BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 21273244)

  • 1. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
    Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
    Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
    Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
    Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy.
    Kuhn C; Frank D; Will R; Jaschinski C; Frauen R; Katus HA; Frey N
    J Biol Chem; 2009 Jun; 284(25):17320-17327. PubMed ID: 19372220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
    Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
    Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter concerning: 'Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo'.
    da Costa Martins PA; De Windt LJ
    Cardiovasc Res; 2011 Sep; 91(4):742-3; author reply 743-4. PubMed ID: 21795320
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcineurin regulates NFAT-dependent iNOS expression and protection of cardiomyocytes: co-operation with Src tyrosine kinase.
    Obasanjo-Blackshire K; Mesquita R; Jabr RI; Molkentin JD; Hart SL; Marber MS; Xia Y; Heads RJ
    Cardiovasc Res; 2006 Sep; 71(4):672-83. PubMed ID: 16828070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of nerve growth factor in the heart: the role of the calcineurin-NFAT pathway.
    Rana OR; Saygili E; Meyer C; Gemein C; Krüttgen A; Andrzejewski MG; Ludwig A; Schotten U; Schwinger RH; Weber C; Weis J; Mischke K; Rassaf T; Kelm M; Schauerte P
    J Mol Cell Cardiol; 2009 Apr; 46(4):568-78. PubMed ID: 19150448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy.
    Li HL; Yin R; Chen D; Liu D; Wang D; Yang Q; Dong YG
    J Cell Biochem; 2007 Apr; 100(5):1086-99. PubMed ID: 17266062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
    Hille S; Dierck F; Kühl C; Sosna J; Adam-Klages S; Adam D; Lüllmann-Rauch R; Frey N; Kuhn C
    Cardiovasc Res; 2016 Jun; 110(3):381-94. PubMed ID: 27056896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
    Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
    J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro.
    Pu WT; Ma Q; Izumo S
    Circ Res; 2003 Apr; 92(7):725-31. PubMed ID: 12663489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
    Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC
    Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
    Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.
    Molkentin JD
    Cardiovasc Res; 2004 Aug; 63(3):467-75. PubMed ID: 15276472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin-induced cardiomyocyte hypertrophy reveals both calcium-dependent and calcium-independent/RhoA-dependent calcineurin activation and NFAT nuclear translocation.
    Rajapurohitam V; Izaddoustdar F; Martinez-Abundis E; Karmazyn M
    Cell Signal; 2012 Dec; 24(12):2283-90. PubMed ID: 22917533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.
    Lister K; Autelitano DJ; Jenkins A; Hannan RD; Sheppard KE
    Cardiovasc Res; 2006 Jun; 70(3):555-65. PubMed ID: 16533503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
    Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
    Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
    Braz JC; Bueno OF; Liang Q; Wilkins BJ; Dai YS; Parsons S; Braunwart J; Glascock BJ; Klevitsky R; Kimball TF; Hewett TE; Molkentin JD
    J Clin Invest; 2003 May; 111(10):1475-86. PubMed ID: 12750397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.